In summary, our work delineates how the AMPK-regulated SP1 pathway leads to diabetes-responsive transcription of dynein genes, provides a better understanding of the initial steps of dynein-driven pathogenesis of DN, and identifies a new molecular target for remodeling dynein-mediated pathology in vivo. The gene discussed is SP1; the disease is liver dysplastic nodule.